Form 8-K - Current report:
SEC Accession No. 0001193125-23-068545
Filing Date
2023-03-13
Accepted
2023-03-13 08:51:38
Documents
53
Period of Report
2023-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d385129d8k.htm   iXBRL 8-K 28285
2 EX-99.1 d385129dex991.htm EX-99.1 57066
6 GRAPHIC g385129ex99_1p10g1.jpg GRAPHIC 281978
7 GRAPHIC g385129ex99_1p11g1.jpg GRAPHIC 306913
8 GRAPHIC g385129ex99_1p12g1.jpg GRAPHIC 239079
9 GRAPHIC g385129ex99_1p13g1.jpg GRAPHIC 198945
10 GRAPHIC g385129ex99_1p14g1.jpg GRAPHIC 259952
11 GRAPHIC g385129ex99_1p15g1.jpg GRAPHIC 390598
12 GRAPHIC g385129ex99_1p16g1.jpg GRAPHIC 246301
13 GRAPHIC g385129ex99_1p17g1.jpg GRAPHIC 390164
14 GRAPHIC g385129ex99_1p18g1.jpg GRAPHIC 314655
15 GRAPHIC g385129ex99_1p19g1.jpg GRAPHIC 283992
16 GRAPHIC g385129ex99_1p1g1.jpg GRAPHIC 263518
17 GRAPHIC g385129ex99_1p20g1.jpg GRAPHIC 239587
18 GRAPHIC g385129ex99_1p21g1.jpg GRAPHIC 243414
19 GRAPHIC g385129ex99_1p22g1.jpg GRAPHIC 167290
20 GRAPHIC g385129ex99_1p23g1.jpg GRAPHIC 312521
21 GRAPHIC g385129ex99_1p24g1.jpg GRAPHIC 260580
22 GRAPHIC g385129ex99_1p25g1.jpg GRAPHIC 271052
23 GRAPHIC g385129ex99_1p26g1.jpg GRAPHIC 171100
24 GRAPHIC g385129ex99_1p27g1.jpg GRAPHIC 197227
25 GRAPHIC g385129ex99_1p28g1.jpg GRAPHIC 103607
26 GRAPHIC g385129ex99_1p29g1.jpg GRAPHIC 37104
27 GRAPHIC g385129ex99_1p2g1.jpg GRAPHIC 383097
28 GRAPHIC g385129ex99_1p30g1.jpg GRAPHIC 336422
29 GRAPHIC g385129ex99_1p31g1.jpg GRAPHIC 319258
30 GRAPHIC g385129ex99_1p32g1.jpg GRAPHIC 306280
31 GRAPHIC g385129ex99_1p33g1.jpg GRAPHIC 322081
32 GRAPHIC g385129ex99_1p34g1.jpg GRAPHIC 292502
33 GRAPHIC g385129ex99_1p35g1.jpg GRAPHIC 295959
34 GRAPHIC g385129ex99_1p36g1.jpg GRAPHIC 282954
35 GRAPHIC g385129ex99_1p37g1.jpg GRAPHIC 197295
36 GRAPHIC g385129ex99_1p38g1.jpg GRAPHIC 304543
37 GRAPHIC g385129ex99_1p39g1.jpg GRAPHIC 208930
38 GRAPHIC g385129ex99_1p3g1.jpg GRAPHIC 384265
39 GRAPHIC g385129ex99_1p40g1.jpg GRAPHIC 288283
40 GRAPHIC g385129ex99_1p4g1.jpg GRAPHIC 287619
41 GRAPHIC g385129ex99_1p5g1.jpg GRAPHIC 253261
42 GRAPHIC g385129ex99_1p6g1.jpg GRAPHIC 290098
43 GRAPHIC g385129ex99_1p7g1.jpg GRAPHIC 314876
44 GRAPHIC g385129ex99_1p8g1.jpg GRAPHIC 256494
45 GRAPHIC g385129ex99_1p9g1.jpg GRAPHIC 275725
  Complete submission text file 0001193125-23-068545.txt   15088151

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acrv-20230313.xsd EX-101.SCH 2838
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrv-20230313_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrv-20230313_pre.xml EX-101.PRE 11699
47 EXTRACTED XBRL INSTANCE DOCUMENT d385129d8k_htm.xml XML 3459
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 23725880
SIC: 2834 Pharmaceutical Preparations